Assessment of metabolic disorders in patients with prostate cancer receiving luteinizing hormone-releasing hormone agonists

• Aleksandr A. Kozhevnikov
• Elena Yu. Gritskevich
• Tatyana Yu. Demidova

Abstract

Therapy with luteinizing hormone-releasing hormone agonists (aLHRH) is the main method of androgen-deprivation therapy (ADT) for prostate cancer (PCa). Such therapy is accompanied by side effects: sarcopenia, metabolic disorders, osteoporosis, etc. This study is devoted to assess the state of carbohydrate and lipid metabolism in patients with locally advanced prostate cancer (pT3N 0M0) and biochemical recurrence (PSA >0.2 ng/dL) during aLHRH therapy. We had been estimating the change of glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) level; fat metabolism parameters: total cholesterol (TC) and triglycerides (TG); body mass index (BMI) and waist circumference (WC) of the participants from the Clinical Hospital named after D.D. Pletnev's of the Moscow Health Department after 3, 6 and 12 months after therapy initiation during 2014-2019. According to the results of the study, a statistically significant increase in these indicators was observed, marked most during first 3 months (with the greatest relative increase TG). Thus, we can assume a rational approach to post-intervention monitoring of carbohydrate metabolism parameters (HbA_1c, FPG), weight (BMI, WC), TC and TG after 3 months, and then 1 year after the start of hormonal treatment. However, further research is needed to assess the applicability and effectiveness of this approach in clinical practice.

Keywords:androgen deprivation therapy, prostate cancer, LHRH agonists, body mass index, fasting plasma glucose, HbA1c

References

1. Artibani W., et al. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018; 100 (3): 251-62.

2. Choi S.M., Kam S.C. Metabolic effects of androgen deprivation therapy. Korean J Urol. 2015; 56 (1): 12-8.

3. Crawford E.D., et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019; 22 (1): 24-38.

4. Wadosky K.M., Koochekpour S. Therapeutic rationales, progresses, failures, and future directions for advanced prostate cancer. Int J Biol Sci. 2016; 12 (4): 409-26.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)